M&A Deal Summary

Ascendent Capital Partners Acquires SciClone Pharmaceuticals

On June 8, 2017, private equity firm Ascendent Capital Partners acquired life science company SciClone Pharmaceuticals for 605M USD

Acquisition Highlights
  • This is Ascendent Capital Partners’ 1st transaction in the Life Science sector.
  • This is Ascendent Capital Partners’ 2nd largest (disclosed) transaction.
  • This is Ascendent Capital Partners’ 1st transaction in the United States.
  • This is Ascendent Capital Partners’ 1st transaction in California.

M&A Deal Summary
Date 2017-06-08
Target SciClone Pharmaceuticals
Sector Life Science
Buyer(s) Ascendent Capital Partners
Deal Type Going Private
Deal Value 605M USD
Advisor(s) Lazard (Financial)
DLA Piper (Legal)

Target

SciClone Pharmaceuticals

Foster City, California, United States
SciClone Pharmaceuticals is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as an immune system enhancer, according to the local regulatory approvals. SciClone Pharmaceuticals was founded in 1989 and is based in Foster City, California.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ascendent Capital Partners

Investor Investor Investor Investor Investor

Category Private Equity Firm
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

Ascendent Capital Partners is a private equity firm focused on acquiring and investing in China-related companies. The Firm looks to leverage its network and experience when working with and helping companies grow. Ascendant Capital Partners has offices in Shanghai and Hong Kong.

DEAL STATS #
Overall 2 of 4
Sector (Life Science) 1 of 1
Type (Going Private) 1 of 2
State (California) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-05-15 Meituan

Beijing, China

Meituan is a technology retail company that offers to promote digital upgrades of service retail and commodity retail on both the demand and supply sides, and works with its partners to provide quality services to consumers. Meituan was founded in 2003 and is based in Beijing, China.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-20 Meituan

Beijing, China

Meituan is a technology retail company that offers to promote digital upgrades of service retail and commodity retail on both the demand and supply sides, and works with its partners to provide quality services to consumers. Meituan was founded in 2003 and is based in Beijing, China.

Sell -
Mergr

Product

Company

Legal